進階篩選

Technical category
  • 共有:4筆資料
  • 顯示:
  • 筆商品
    • 百發百中、相醫維命 – 發展伴隨式診斷以進行小分子RNA干擾片段的癌症精準醫療

      Precision Health Ecosystem FutureTech 百發百中、相醫維命 – 發展伴隨式診斷以進行小分子RNA干擾片段的癌症精準醫療

      Cancer is the first leading cause of death in Taiwan. Targeted therapy allows the cancer cells to be specifically targeted, reduces the side effects,achieves the purpose of precision cancer treatment. This report contains two invention technologies which combined early & specific diagnosis of a specific Aurora-A mRNA isoform in cancers (the companion diagnosis)the treated with a selective locked nucleic acid (LNA)-modified novel double-stranded short interfering nucleic acid (siRNA) to inhibit the translation of this Aurora-A mRNA isoform (targeted therapy) in cancers.
    • Germplasm Bank of Medicinal Coral Producing New Targeted Anti-cancer Agenttheir Aquaculture Technology Platform

      Precision Health Ecosystem FutureTech Germplasm Bank of Medicinal Coral Producing New Targeted Anti-cancer Agenttheir Aquaculture Technology Platform

      The present invention discloses the germplasm bank of medicinal coral producing new targeted anti-cancer agent and their aquaculture technology platform. The medicinal corals are collected in Kenting, located at the southern tip of Taiwan. In response to the unmet medical needs of new anti-cancer drugs, our research results will provide more diverse types of new drug targets and lead compounds in the "new drug development-new drug discovery and exploration period".
    • BPR1R系列:新穎集落刺激因子1受體抑制劑作為癌症免疫調節劑

      FutureTech BPR1R系列:新穎集落刺激因子1受體抑制劑作為癌症免疫調節劑

      We have identified a series of BPR1R compounds as highly selective CSF1R inhibitors with excellent oral bioavailability. In vivo, oral administration of BPR1R compounds delayed murine colon tumor growthreversed the immunosuppressive TME with increased M1/M2 ratio. The US & PCT patent application including more than 160 novel compounds was filed in April 20, 2020. Several potential compounds are undergoing candidate assessment for further preclinical studies.
  • 1